Novo Nordisk gets 2.0 mg Ozempic dose approved in US
The pharmaceutical firm expects to launch 2.0 mg doses of Ozempic in the US during the second quarter of 2022.
by marketwire, translated by catherine brett
The US Food and Drug Administration (FDA) has approved Ozempic in a 2.0 mg dose for the treatment of adults with type 2 diabetes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
